Factor VIII Purification via Chromatography and Furin Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for purifying Factor VIII subspecies are inefficient, leading to impurities and reduced stability of recombinant FVIII products, which can induce immune responses and require frequent administrations due to short half-lives and antibody development.
Innovation Solution
A method involving anion exchange chromatography, size exclusion chromatography, and concentration steps, including furin protease treatment and extended gradient elution, to achieve high purity and concentration of FVIII subspecies, reducing aggregation and increasing activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If current purification methods are used for Factor VIII subspecies, then the purification process is simpler, but the purity and stability of the recombinant FVIII product are reduced
Solution Approach 1:
The purification process is divided into multiple sequential chromatography steps (anion exchange, size exclusion, and concentration steps) to progressively separate and purify different FVIII subspecies. Each step targets specific impurities or subspecies based on their physical-chemical properties, achieving high purity through staged separation rather than a single complex step.
Solution Approach 2:
Furin protease is introduced as an intermediary enzyme to selectively cleave and remove specific subspecies or impurities during the purification process. The protease acts as a mediator that modifies the FVIII composition to facilitate subsequent separation and purification steps, enhancing overall purity.
2Loss of time
If current purification methods are used for Factor VIII subspecies, then the purification process is faster, but aggregation increases and activity decreases
Solution Approach 1:
The purification protocol includes preliminary steps such as furin protease treatment and specific buffer conditions applied before the main chromatography steps. These preliminary actions prepare the FVIII subspecies by reducing aggregation propensity and optimizing their physical-chemical properties, ensuring better separation efficiency and higher stability in the final product.
Solution Approach 2:
The method employs controlled changes in chromatographic parameters (gradient elution profiles, buffer pH, ionic strength) and concentration conditions to optimize the separation and stabilization of FVIII subspecies. By carefully adjusting these parameters, the process achieves both rapid purification and high product stability, preventing aggregation while maintaining biological activity.
3Quantity of substance
If purification is insufficient, then the production cost is lower, but immune responses are induced and half-life is reduced
Solution Approach 1:
The purification method specifically extracts and removes aggregation-prone subspecies and impurities through the multi-step chromatography process. By selectively taking out harmful components (aggregates, incorrect subspecies) while concentrating the desired FVIII subspecies, the method achieves high purity that prevents immune responses and extends half-life, while maintaining high concentration of the therapeutic product.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method results in purified FVIII subspecies with improved stability, reduced propensity for aggregation, and enhanced activity, potentially leading to more effective and prolonged therapeutic effects for hemophilia A treatment.
Implementation Method 1
employing two chromatography steps, namely an anion exchange chromatography step and a size exclusion chromatography step
Implementation Method 2
employing two chromatography steps, namely an anion exchange chromatography step and a size exclusion chromatography step
Data Source
AI summary
The present invention relates to a method for purifying a Factor VIII (FVIII) subspecies from a composition comprising FVIII, said method comprising an anion exchange chromatography step, a size exclusion chromatography step, and a concentration step. The invention also relates to a composition comprising a purified FVIII subspecies.